Core Viewpoint - Tonghua Dongbao's liraglutide injection has received GMP certification from Brazil's ANVISA, marking a significant step in the product's compliance process in the Latin American market and strengthening its internationalization strategy for GLP-1 products [1][2] Group 1: Product and Market Development - Liraglutide, a GLP-1 analog, activates GLP-1 receptors to promote insulin secretion, improve blood sugar levels, and provide cardiovascular protection and weight loss benefits, gaining global recognition for its efficacy and safety [1] - Brazil, with a population of approximately 210 million and a growing diabetes patient base, presents a strong market demand for GLP-1 products, which are effective in glycemic control and weight management [2] Group 2: International Strategy and Achievements - Since 2025, Tonghua Dongbao has accelerated its internationalization strategy, achieving significant progress in overseas registrations and expanding its product matrix in international markets [2] - The recent GMP certification in Brazil, following similar achievements in Colombia and Peru, indicates a systematic layout in the Latin American market and lays a foundation for entering other PIC/S member countries [2] Group 3: Competitive Landscape - The domestic market for GLP-1 drugs in China is highly competitive, and obtaining the GMP certification in Brazil opens a new sales channel for Tonghua Dongbao, helping to extend the product lifecycle and realize incremental value in overseas markets [2]

Core Insights - The article highlights the successful international approval of Liraglutide injection by Tonghua Dongbao Pharmaceutical Co., Ltd. in Peru, marking a significant milestone in the company's global expansion strategy in the GLP-1 product category [4] - Liraglutide, a GLP-1 analog, is recognized for its efficacy in improving blood sugar levels, cardiovascular protection, and weight loss, gaining global acceptance [4] Market Growth and Strategy - The International Diabetes Federation (IDF) projects that the number of adults aged 20-79 with diabetes will reach 589 million in 2024, with a prevalence rate of 11.1%, and is expected to rise to 853 million by 2050, indicating a growing market for diabetes treatments [6] - The company, in collaboration with Sinovac Biotech, is targeting emerging markets with high diabetes prevalence, covering 17 countries across Latin America, the Middle East and North Africa, Southeast Asia, and South Africa [6] Product Development and Internationalization - The company has achieved significant progress in international registrations for multiple products, including Liraglutide and insulin formulations, with approvals in Indonesia, Uzbekistan, and other emerging markets [7] - The internationalization strategy is set to accelerate, aiming to expand overseas sales and provide accessible diabetes treatment options to a broader patient base [7]